Transvaginal Sacrospinous Hysteropexy Versus Laparoscopic Uterine Lateral Suspension

Sponsor
National Cheng-Kung University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05586984
Collaborator
(none)
90
1
89.2
1

Study Details

Study Description

Brief Summary

Transvaginal or transabdominal surgeries are current choices of uterus-preserving surgeries for pelvic organ prolapse.

Laparoscopic lateral uterine suspension, a modified surgical approach of uterine suspension from bilateral abdominal wall fascia, performed with expected safety and simplicity of surgery besides advantages including small wound incision and fast recovery in laparoscopic surgeries. This trial aim to discuss the therapeutic efficacy, long term safety, and adverse events of laparoscopic lateral uterine suspension and compare with the conventional transvaginal sacrospinous ligament fixation with native tissue repair.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic uterine lateral suspension
  • Procedure: Transvaginal sacrospinous fixation

Detailed Description

Pelvic organ prolapse can be treated either conservatively or surgically. Patients who are unsatisfied with conservative treatment or with severe symptoms often seek for surgical intervention. Transvaginal or transabdominal surgeries are current choices of uterus-preserving surgeries for pelvic organ prolapse. Laparoscopic sacrohysteropexy is the current trend for laparoscopic surgery, with small incisional wound, fast recovery, and low recurrence rate as advantages. However, laparoscopic sacrohysteropexy is often regarded as time consuming and ous sometimes hazard given the complexity of surgical technique and the anatomy of the presacral region. Few cases with severe complications such as vascular injuries, sacral nerve root injuries, and diskitis had been reported with laparoscopic sacrohysteropexy in previous studies.

Laparoscopic lateral uterine suspension, a modified surgical approach of uterine suspension from bilateral abdominal wall fascia, is therefore proposed in our study. The most significant benefits of this novel approach include safety and simplicity of surgery besides advantages including small wound incision and fast recovery in laparoscopic surgeries. This trial aim to discuss the therapeutic efficacy of laparoscopic lateral uterine suspension and compare with the transvaginal sacrospinous ligament fixation with native tissue repair. Other results include safety and adverse events of laparoscopic lateral uterine suspension in long term follow up.

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective, Observational Trial of Transvaginal Uterine Suspension With the New Minimally Invasive Uterine Suspension
Actual Study Start Date :
Jul 26, 2022
Anticipated Primary Completion Date :
Dec 31, 2029
Anticipated Study Completion Date :
Dec 31, 2029

Arms and Interventions

Arm Intervention/Treatment
Laparoscopic uterine lateral suspension

Laparoscopic uterine lateral suspension for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.

Procedure: Laparoscopic uterine lateral suspension
Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.

Transvaginal sacrospinous fixation

Uterus-preserving transvaginal sacrospinous fixation for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.

Procedure: Transvaginal sacrospinous fixation
Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.

Outcome Measures

Primary Outcome Measures

  1. Recurrence [5 years]

    Composite outcome of subjective and objective recurrence of uterine prolapse.

Secondary Outcome Measures

  1. Anatomical outcome [5 years]

    Comparison of total vaginal length (TVL), Ba, Bp points defined by POP-Q system.

  2. Functional outcome [5 years]

    Comparison of urination and defecation functions by Pelvic floor disability index-20 (PFDI-20).

  3. Sexual function outcome [5 years]

    Comparison of sexual function by Female Sexual Function Index (FSFI).

  4. Urodynamic outcome [6 months]

    Comparison of post residual urine amount, uroflowmetry, and 1-hour pad test.

Other Outcome Measures

  1. Safety outcome [5 years]

    Surgery-related complications and mesh-related long term complications.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • older than 21 years old.

  • uterine prolapse stage 2 at least, defined by C point distal to -1cm by POP-Q system.

  • patients willing to receive a uterine-preserving surgery for pelvic organ prolapse, and is suitable for anesthesia after evaluation.

  • patients who had or had not received conservative treatments for pelvic organ prolapse.

  • patients able and willing to finish the questionnaire evaluation.

Exclusion Criteria:
  • patient who had received a previous hysterectomy, or is planning on concomitant hysterectomy in the surgery for pelvic organ prolapse.

  • patient who had received a previous surgery for pelvic organ prolapse.

  • patient with history of adverse events following a synthetic mesh.

  • patients with chronic or acute pelvic pain.

  • patients who had received abdominal or pelvic irradiation.

  • patients who cannot receive either surgery due to comorbidity.

  • patients pregnant or with future plan of pregnancy.

  • patients with vaginal length less than 5cm.

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Cheng Kung University Hospital Tainan Taiwan

Sponsors and Collaborators

  • National Cheng-Kung University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yu Fang Huang, Professor Yu Fang Huang, National Cheng-Kung University Hospital
ClinicalTrials.gov Identifier:
NCT05586984
Other Study ID Numbers:
  • 111-NCKUH-CTC--IIT
First Posted:
Oct 19, 2022
Last Update Posted:
Oct 21, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yu Fang Huang, Professor Yu Fang Huang, National Cheng-Kung University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 21, 2022